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In vivo effect of cellular calcium uptake on osmotic
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In vivo effect of cellular calcium uptake on osmotic and nonosmotic
release of arginine vasopressin. In vitro studies have suggested that the
concentration of calcium (Ca) in the bathing medium may be important
for the release of arginine vasopressin (AVP). The present experiments
were undertaken to investigate the in vivo role of cellular Ca uptake in
the osmotic and nonosmotic release of AVP in conscious hydrated rats.
Experimental rats were infused intravenously with two different
blockers of cellular Ca uptake, while control rats were infused only with
the vehicles for these agents. The antidiuresis following the infusion of
3% saline was attenuated significantly in verapamil-treated rats, as
urinary osmolality (Uom) rose in these animals to only 595 26
mOsm/kg H20 as compared to 743 49 mOsm/kg H20 (P < 0.025) in
controls. Likewise, plasma AVP levels during 3% saline infusion rose to
10.7 1.9 pg/mi in verapamil-treated rats, a value significantly lower
than the value of 19.1 3.1 pg/mi in the control rats (P < 0.05). Similar
results were obtained with nifedipine. Following 3% saline infusion the
peak Uom of 601 27 mOsm/kg H20 in nifedipine-treated rats was
significantly lower than rats of 756 39 mOsm/kg H20 (P < 0.01) in
controls. This decrease in Uosm also was associated with a lower level
of plasma AVP in nifedipine-treated rats of 10.3 1.3 pg/mI versus 18.9
3.6 pg/mi in the control rats (P < 0.05). In another group of rats the
nonosmotic release of AVP was examined during hypovolemia induced
by intraperitoneal 6% dextran. Following intraperitoneal dextran the
mean peak Uom of 476 74 mOsm/kg H20 in the verapamil-treated
rats was significantly less than 1069 88 mOsm/kg H20 in the control
rats (P < 0.001) despite a comparable decrease in blood volume. The
decrease in Uom also was associated with lower levels of plasma AVP
in the verapamil-treated rats of 4.3 1.2 pg/mI versus 12.8 2.2 pg/mI
in control rats (P < 0.01). Similar results were obtained with nifedipine.
Following intraperitoneal administration of dextran, the peak Uo.m rose
to only 479 78 mOsm/kg H20 after nifedipine as compared to 943 88
mOsm/kg H20 in controls (P < 0.005). Likewise, plasma AVP rose to
only 4.1 1.1 pg/mi in nifedipine-treated rats versus 10.8 2.6 pg/mI in
their controls (P < 0.05). Therefore, these results demonstrate that
cellular Ca uptake is an important factor in modulating both the osmotic
and nonosmotic release of AVP in conscious rats.
Effet de I'entrée de calcium dans Ia cellule in vivo sur Ia sécrétion
osmotique et non osmotique de l'arginine vasopressine. Des etudes in
vitro suggèrent que Ia concentration de calcium (Ca) dans le milieu
pourrait avoir un role important dans Ia sécrétion d'arginine vasopres-
sine (AVP). Ce travail a eté entrepris afin de préciser le rOle de l'entrée
du Ca dans la cellule in vivo sur la secretion osmotique et non
osmotique d'AVP chez des rats conscients hydrates. Les rats expéri-
mentaux etaient perfusCs par voie intraveineuse avec deux bloqueurs
différents de l'entrée cellulaire du calcium, et les rats contrôle étaient
perfuses uniquement avec les véhicules de ces substances. L'antidiur-
Cse consecutive a perfusion de solute sale a 3% était significativement
attenuee chez les rats traites par du Verapamil, puisque l'osmolalité
urinaire (Uosm) ne s'élevait chez ces animaux qui 595 26 mOsm/kg
H20 seulement, contre 743 49 mOsm/kg H20 (P < 0,25) chez les
contrOles. De méme, les concentrations plasmatiques de l'AVP pendant
la perfusion de solute sale a 3% s'étaient elevees a 10,7 1,9 pg/mI chez
les rats traites au Verapamil, valeur significativement plus faible que
celle obtenue chez les rats contrôles (19,1 3,1 pg/mI, P < 0,05). Des
résultats identiques ont ete obtenus avec Ia Nifedipine. Aprés Ia
perfusion de solute sale a 3%, l'osmolalité maximale etait de 601 27
mOsm/kg H20 chez les rats traités par Ia Nifedipine, une valeur
significativement plus basse que chez les rats contrOles (756 39
mOsm/kg, P < 0,01). Cette diminution de Uosm Ctait egalement
associée a une concentration plasmatique plus faible d'AVP chez les
rats traites ala Nifedipine (10,3 1,3 pg/mi au lieu de 18,9 3,6 pg/mI
chez les rats contrôles, P < 0,05). Dans un autre groupe de rats, Ia
secretion non osmotique d'AVP a été étudiée au cours d'une hypovole-
mie induite par l'administration intra-peritoneale de Dextran a 6%.
Après administration intrapéritoneale du Dextran, Uosm maximale
moyenne était de 476 74 mOsm/kg H20 chez les rats traités par
Vérapamil, une valeur significativement plus faible que chez les rats
contrOles (1069 88 mOsm/kg H20, P < 0,001), malgre une diminution
comparable du volume sanguin. Cette diminution de U0,, etait aussi
associee a des concentrations plasmatiques faibles d'AVP chez des rats
traites par le Vérapamil (4,3 1,2 pg/mI, contre 12,8 2,2 pg/mI chez
les rats contrôle P < 0,01). Des résultats identiques ont été obtenus
avec Ia Nifedipine. Aprés i'administration intraperitoneale de Dextran,
Uosm maximum n'etait que de 479 78 mOsm/kg H20 après Nifedipine
au lieu de 943 88 mOsm/kg H20 chez les contrôies (P < 0,005). De
mCme, i'AVP plasmatique ne s'est dlevée qu'à4,l 1,1 pg/mI chez les
rats recevant de Ia Nifedipine, contre 10,8 2,7 pg/mI chez leurs
contrôies (P < 0,05). Ces résuitats démontrent ainsi que i'entrée
celiulaire du calcium est un facteur important pour moduier Ia secretion
osmotique et non osmotique de l'AVP chez des rats eveilles.
The presence of calcium (Ca) in the bathing medium of the
isolated neurohypophysis appears to be important for the in
vitro release of arginine vasopressin (AVP) [1—5]. In the context
of the stimulus-secretion coupling concept, Ca movement into
the neurohypophysis in the process of membrane depolariza-
tion results in the release of AVP. A similar role for Ca influx in
hormone secretion has been described for catecholamine [61,
insulin [7], gonadotropin [8], and oxytocin [91.
There are no in vivo studies which have examined the role of
cellular Ca influx on AVP release. The purpose of the present in
vivo experiments, therefore, is to investigate whether or not
cellular Ca uptake is important in the osmotic and nonosmotic
release of AVP. The results of the present experiments revealed
that the two different blockers of cellular Ca uptake, namely
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Fig. 1. Experimental protocol of the present study.
verapamil and nifedipine, blunt both osmotic and nonosmotic
release of AVP.
Methods
Studies were performed on male Sprague-Dawley rats weigh-
ing 250 to 340 g. The rats were allowed free access to food and
water until the time of the experiment.
Following ether anesthesia, the rats underwent placement of
external jugular vein and carotid artery catheters (PE-50, Clay-
Adams Div., Beckton, Dickinson & Co., Parsippany, New
Jersey) as well as suprapubic polyethylene catheters (PE-l00,
Clay-Adams Div.) into the urinary bladder. Then the animals
were placed in a restrainer (Narco Biosystems, Inc., Houston,
Texas) and allowed to awaken. At least 30 mm passed before
experiments were started.
Hypertonic saline protocol (Fig. 1). The animals were infused
with 0.3% saline containing 1.2 g!dl inulin at a rate of 6 mI/hr
(model 355, Sage Instruments Div., Orion Research Inc.,
Cambridge, Massachusetts) to achieve a water diuresis. When a
volume equivalent to 2 to 3% of body weight was administered,
most rats had a urinary osmolality (Uosm) of 150 mOsm/kg H20
or below. Only these rats were used in the subsequent experi-
ments. When a stable water diuresis was established, three 5-
mm control urine collections were obtained for measurements
of urine volume, UOsm, and inulin concentration. At the same
time a 0.5-mi blood sample was collected for the measurements
of hematocrit (Hct), plasma osmolality (P0sm), and inulin
concentration.
After this control period, the experimental rats were infused
with either of two blockers of cellular Ca uptake, verapamil (100
p.glkg/min, Knoll Pharmaceutical Co., Whippany, New Jersey)
or nifedipine (15 p.glkg/min, Pfizer Pharmaceuticals Co., New
York, New York) at a rate of 2 mI/hr. The control groups of rats
were infused with the respective vehicles of these two Ca
blockers at the same infusion rate. Verapamil was dissolved in
0.9% saline, while nifedipine was dissolved in the solution
containing ethanol, polyethylene glycol, and distilled water
(15:15:70, vlv). The infusions of drugs or their vehicles were
maintained throughout the rest of the experiment. Three 5-mm
urine collections and a 0.5-ml blood sample were taken for the
measurement of the same indices as described above 30 mm
after the infusion of the blockers of cellular Ca uptake or their
vehicles were started. After this collection the response to an
osmotic stimulus was tested with an infusion of 3% sodium
chloride (2 ml/lOO g body wt) administered over a 4 to 5-mm
period. After completing the infusion, the urine was collected at
5-mm intervals for 60 mm and 0.2 ml blood samples were taken
at 15-mm intervals for 60 mm. Blood removed was replaced
with equivalent volumes of isotonic saline.
Another group of equally treated experimental and control
rats received the hypertonic saline and had plasma AVP mea-
surements. Since the peak Usm after the infusion of hypertonic
saline was found to occur between 18 and 23 mm in our earlier
experiments [10], a 2.0-ml blood sample was taken rapidly over
10 sec through the arterial catheter exactly 20 mm after the
beginning of the hypertonic saline infusion. It was established
previously in our laboratory that blood removal over 10 sec did
not stimulate plasma levels of AVP rapidly enough to effect the
AVP content in the withdrawn specimen [10].
Hyperoncotic dextran protocol (Fig. 1). The intraperitoneal
administration of 6% dextran T-70 (Pharmacia Fine Chemicals,
Inc., Piscataway, New Jersey) was used as a nonosmotic,
hypovolemic stimulus to AVP release. Rats used in this experi-
ment were prepared in the same manner as described above,
with the exception of placement of an intraperitoneal catheter
(PE-350, Clay-Adams) at the time of surgery. After establishing
a water diuresis, control collections of blood and urine samples
were obtained, followed by the infusion of verapamil (50
p.g/kg/min), nifedipine (7.5 p.g/kg/min) or their vehicles as
described in the hypertonic saline protocol. Then the animals
were given an intraperitoneal injection of dextran (1.8 ml/l00 g
body wt) at a rate of 1 ml/min. The estimated oncotic pressure
of this solution (van't Hoff equation) is 800 mm H20. After
intraperitoneal dextran was injected, the experimental periods
were started and urine was collected at 5-mm intervals. Blood
was taken every 15 mm for 60 mm. Blood removed was
replaced with equivalent volumes of isotonic saline. Calculation
of estimated changes in blood volume (BY) was done by the
formula [BV = 1 — (Hct 2/Ret I)]. This method probably
underestimates zIBV because it does not account for erythro-
cyte volume removed by blood sampling.
In a separate group of experimental and control rats, blood
samples were taken for the determination of AVP. Because the
peak Uosm after the injection of dextran was found to occur
between 30 and 60 mm in our earlier experiments, 2.0-mi blood
samples were taken rapidly over 10 sec through the arterial
catheter exactly 40 mm after the start of experimental periods.
Studies on the effect of blockade of cellular calcium uptake
on the renal response to exogenous vasopressin. To ascertain
whether or not any of the observed changes in UOsm in rats
receiving the Ca blockers was due to an alteration in the renal
response to AVP the response to exogenous hormone was
tested. The rats were prepared in the same manner as described
above. After establishing a water diuresis, three control urine
collections were obtained. Immediately after these collections,
400 U AVP (Aqueous Pitressin, Parke-Davis & Co., Detroit,
Michigan) were administered i.v. Three-minute urine collec-
tions were taken until Uosm returned to below 150 mOsm/kg
H2O. The collections were followed by the administration of
verapamil (50 g/kg/min, N = 7) or nifedipine (7.5 g/kg/min, N
= 5). Forty-five minutes later three control urine collections
were again obtained, and then a second bolus of 400 p.U AVP
was administered. Urine collections were continued until UOsm
again decreased to below 150 mOsm/kg H20. This protocol
therefore allows the comparison of the renal response to
sequential boluses of AVP before and after administration of a
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blocker of Ca uptake in the same rat. Previous experiments in
our laboratory have shown that the serial administration of
AVP in control rats yields a comparable antidiuresis [11].
In all studies blood pressure was monitored throughout the
experiment by a strain gauge (Statham Instruments, Oxnard,
California). Hct was measured by a micro hematocrit tube
reader (model CR, International Equipment Co., Div. Damon
Corp., Needham Heights, Massachusetts). Osm was measured
by a vapor pressure osmometer (Wescor Inc., Logan, Utah),
and U0sm by freezing-point depression (Model 3R, Advanced
Instruments, Inc., Needham Heights, Massachusetts). The
vapor pressure osmometer correlates within 1% of the value
recorded by both freezing-point depression and calculated
osmolality [121. Inulin concentration was measured by an
autoanalyzer (Technicon Instruments Corp., Tarrytown, New
York).
Arginine vasopressin measurement. All blood samples for the
measurement of AVP were taken by heparinized syringes and
then transferred to glass tubes on ice. These samples were
centrifuged at 40 C at 2000 rpm (Model PR-J, International
Equipment Co., Needham Heights, Massachusetts) for 10 mm.
The plasma was removed and frozen at _200 C until the
specimens were thawed and AVP was measured. These sam-
ples were extracted by the method of Robertson et al [131.
Acetone extracts were prepared by mixing 1 ml of plasma with 2
ml of cold acetone. After centrifugation at 3000 rpm for 20 mm,
the supernatant is decanted from the precipitate, thoroughly
mixed with 5 ml of cold ether and centrifuged again; the top
phase is aspirated carefully and discarded. The acetone remain-
ing in the lower aqueous phase was eliminated under a stream of
room air. The precipitations were dissolved in 0.5 ml of
phosphate buffered saline and then yielded to measure by
radioimmunoassay [141.
The lower limit of detection of the standard curves is 0.5
pg/mI. A Ferring (Malmo, Sweden) AVP reference preparation
(400 U/mg) is used as the standard curves. Intra- and inter-assay
coefficients of variation are 14% and 13.7%, respectively.
Oxytocin crossreacted by less than 0.1% with the AVP antise-
rum, while lysine vasopressin showed 10% immunoreactivity
when compared with AVP.
Statistics. In each rat, mean Uosm, Osm, mean arterial
pressure, Hct, and inulin clearance at the time of peak Uosm
were compared to their mean values during control periods of
the same rats by paired Student's t test. These parameters as
well as plasma AVP levels also were compared between the
groups of control and experimental rats by unpaired Student's
test. A P value of less than 0.05 was considered significant.
Results
Hypertonic saline study. During the control period the POsm
was similar in the four groups of water diuresing rats as is
depicted in Figure 2. The administration of verapamil, nifedi-
pine, and their vehicles did not change POsm. Following the
infusion of 3% sodium chloride, there was an equivalent in-
crease in POsm (approximately 20 mOsm/kg H20) in all groups
of rats. During the control period a water diuresis was achieved
in all the groups (Fig. 2). The administration of verapamil and
nifedipine did not increase significantly Uosm despite a decrease
in systemic pressure (vide infra). The four groups of animals
had a significant (P < 0.001) antidiuresis in association with the
infusion of hypertonic sodium chloride. However, the peak
Uosm was slightly but significantly lower in the groups of
animals receiving both blockers of cellular Ca uptake as com-
pared to their own control animals (Fig. 2). Specifically, peak
Uosm rose to 595.0 25.7 mOsm/kg H20 in verapamil-treated
rats (N = 7), a value significantly lower than the value in the
control rats of 742.8 48.7 mOsm/kg H20 (N = 7, P < 0.025).
Likewise, peak Uo was 601.3 27.5 mOsm/kg H20 in
nifedipine-treated rats (N = 7); this value was significantly
lower than the Uosm in the control rats of 756.3 38.9 mOsm/
kg H20 (N = 7, P < 0.01). Table 1 shows that verapamil and
nifedipine caused a decrease in mean arterial pressure (P <
0.001). Furthermore, there was also a significant difference in
mean arterial pressure between the verapamil-treated rats and
their vehicle-treated controls (85.1 2.4 vs. 112.8 2.4 mm
Hg, P < 0.001). Similar results were obtained with nifedipine.
There was no significant differences in Hct and inulin clearance
among any groups of animals during any phase of the
experiments.
The results of plasma AVP levels are shown in Figure 3.
While the plasma AVP level during the control water diuresis
was 0.5 0.2 pg/mI (N = 7), plasma AVP levels 20 mm after the
infusion of hypertonic saline were 19.1 3.1 pg/mI in the
control animals receiving the verapamil vehicle (N = 7), 10.7
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Fig. 2. The response of U00,,, (top panel) and P0,,, (bottom panel) to the
infusion of hypertonic saline. Values given are the mean SEM (N = 7).
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Table 1. Effect of calcium blockers and hypertonic saline on mean arterial pressure, inulin clearance, and hematocrita
Verapamil (N = 7) Vehicle for verapamil (N = 7) Nifedipine (N = 7) Vehicle for nifedipme (N = 7)
Cont Ver HS Cont Veh HS Cont Nif HS Cont Veh MS
MAP, mm Hg
Mean 118.6 95.5" 85.1" 113.7 114.7 112.8 112.3 89.3b 84.1" 115.0 115.8 113.0
1.7 1.7 2.4 1.9 1.9 2.4 2.6 3.4 1.7 2.9 2.4 2.5
P value <0.001 <0.001 NS NS <0.001 NS NS NS
Ci,,, mi/mm
Mean 3.1 2.8 3.1 3.1 3.3 3.2 2.9 3.1 2.9 3.2 3.1 3.1
0.3 0.2 0.3 0.3 0.3 0.1 0.3 0.2 0.1 0.2 0.2 0.2
P value NS NS NS NS NS NS NS NS
Hct, %
Mean 36.9 37.1 37.0 36.7 36.7 36.6 37.0 37.1 37.3 36.7 37.1 37.0
0.6 0.7 0.6 0.5 0.5 0.4 0.3 0.4 0.5 0.7 0.6 0.4
P value NS NS NS NS NS NS NS NS
Abbreviations: Cont, control; Ver, verapamil; Nif, nifedipine; Veh, vehicle; HS, hypertonic saline.
N equals the number of rats used in each study.
b P < 0.001 when compared to vehicle-treated control in same experimental period.
1.9 pg/mi in the verapamil-treated animals (N = 6). The increase
in plasma AVP in the verapamil-treated animals following the
infusion of hypertonic saline was significantly less than the
AVP level in the control rats (P < 0.05). Similar results were
obtained with nifedipine. Specifically, plasma AVP levels after
the infusion of hypertonic saline was 10.3 1.3 pg/mI in the
nifedipine-treated rats (N = 6); this value was significantly
lower than the plasma AVP in control rats of 18.9 3.6 pg/mi
(N = 7, P < 0.05). The plasma AVP levels in all groups of
animals were significantly higher after the infusion of hyperton-
ic saline than that during water diuresis (P < 0.001).
Hyperoncotic dext ran study. In Figure 4 is shown the
changes in blood volume in the four groups of rats after the
intraperitoneal injection of dextran. In each group blood vol-
ume decreased significantly by approximately 10% in all
groups. As in the hypertonic saline studies, the administration
of the blockers and their vehicles did not alter significantly the
Uosm prior to intraperitoneal dextran administration. As shown
in Figure 5, following the administration of intraperitoneal
dextran, all animals had an antidiuresis in response to the
decrease in blood volume. However, the peak Um achieved
was markedly different between control and experimental ani-
mals. Thus, mean peak Uosm after dextran administration
reached 1068.8 87.5 mOsm/kg H20 in control animals (N =
14) but only 476.3 73.7 mOsm/kg H20 in verapamil-treated
animals (N = 14, P < 0.001). Similar results were obtained with
nifedipine. In these studies, mean peak Uosm rose to only 479.2
78.0 mOsm/kg H20 (N = 7) as compared to a mean peak
Uosm of 943.0 87.8 mOsm/kg H20 in controls (N = 7, P <
0.005). The results of changes in mean arterial pressure were
similar to the hypertonic saline study described above and are
shown in Table 2. Mean arterial pressure decreased significant-
ly in the verapamil and niledipine-treated animals compared to
mean arterial pressure during their control periods (P < 0.001).
In addition, there was a significant difference in mean arterial
pressure when the verapamil- and nifedipine-treated animals
and their controls treated with only vehicles are compared (97.1
3.8 vs. 116.0 2.2mm Hg, P <0.01; and 99.4 3.8 vs. 114.5
3.9 mm Hg, P < 0.02). There were no differences in either
inulin clearance or POsm among any groups of animals during
any phase of the experiments.
The results of plasma AVP levels are shown in Figure 6.
Plasma AVP was suppressed during water diuresis (0.6 0.2
pg/mi). After dextran administration, plasma AVP levels in
verapamil-treated rats (N = 7) only rose to 4.3 1.2 pg/mi, a
value significantly lower than the plasma AVP levels of 12.8
2.2 pg/mI in controls (N = 7, P < 0.01). Similar results were
obtained with nifedipine. In these studies, following administra-
tion of intraperitoneal dextran plasma AVP levels in nifedipine-
treated rats, (N = 7) rose to only 4.1 1.1 pg/mi, a value
significantly lower than the plasma AVP levels of 10.8 2.6 pg!
ml in their controls (N = 7, P < 0.05). Piasma AVP levels in all
groups of rats after dextran administration were significantly
higher than during water diuresis (P < 0.005). There was no
difference in piasma AVP ievels between both control groups of
rats after dextran administration.
25
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Fig. 3. Plasma A VP levels during water diuresis and exactly 20 mm
after the infusion of hypertonic saline. Values given are the mean
SEM.
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Fig. 4. Changes in blood volume after the administration of hyperoncot-
ic dextran. The values are expressed as the percent change in blood
volume at the time of the peak Uosm compared to during water diuresis.
Values given are the mean SEM. Shown are the groups of rats
receiving verapamil (N = 14) and its vehicle (N = 14) and the groups of
rats receiving nifedipine (N = 7) and its vehicle (N = 7).
Effect of cellular calcium uptake blockers on the renal
response to exogenous vasopressin. In seven animals, the first
injection of AVP increased Uosm from 102.6 17.6 to 718.0
63.9 mOsmlkg H20 (P < 0.001), and Uosm returned to 144.5
17.4 mOsmlkg H20 (P < 0.001) after the effect of the hormone
dissipated. Following verapamil administration mean Uosm was
129.0 17.7 mOsm/kg H20, the bolus of vasopressin increased
U0sm to 577.4 27.0 mOsm/kg H20 which then fell to 147.0
11.7 mOsmlkg H20 (P < 0.001). In a second group of animals
(N = 5), the first bolus of AVP increased U0 from 120.4 4.5
to 630.6 65.2 mOsm/kg H20 (P < 0.001), and then fell to 130.0
13.1 mOsmlkg H20 (P < 0.001). Following nifedipine admin-
istration, a second injection of AVP increased Uosm from 138.2
10.9 to 567.4 27.1 mOsm/kg H20 (P < 0.001), which then
returned to 145.0 6.5 mOsm/kg H20 (P < 0.001). In both
groups of animals, the response of peak Usm to exogenous
AVP after the infusion of these two blockers was not signifi-
cantly different from the response of peak Uosm to exogenous
AVP before the infusion of these blockers.
Discussion
In 1964 Douglas and Poisner reported that the concentration
of Ca in the bathing media was critical in the release of AVP
from the neurohypophysis [1]. Since that time a number of
other in vitro experiments performed in the isolated neurohy-
pophysis have indicated that Ca ion is involved in the mecha-
nism of AVP release [2—SI. Presumably the influx of Ca that
accompanies membrane depolarization is associated with hor-
mone release. This "stimulus-secretion coupling" is by no
means unique to the posterior pituitary gland and is associated
with the release of other hormones as well [6—8, 15].
Recently, the emergence of pharmacologic agents that alter
the transcellular movement of Ca have provided experimental
tools that can be used to enhance the understanding of Ca
uptake in various biological processes. In this study we used
two chemically different blockers of slow channel Ca uptake
(verapamil and nifedipine) to assess the role of Ca uptake in the
in vivo release of vasopressin. Our initial studies were directed
to determining the effect of increase in extracellular fluid
tonicity (that is, osmotic stimulation) on vasopressin release in
animals treated with Ca membrane blocking agents. The antidi-
uresis associated with an increase in POsm of approximately 20
mOsm/kg H20 was slightly but significantly blunted in the
experimental animals receiving the blockers of Ca uptake when
compared with control animals receiving only the agent's
vehicles. Because the infusion of hypertonic sodium chloride
causes a marked increase in solute excretion that could itself
increase Uosm and obscure a difference in vasopressin release,
we directly measured the levels of this hormone. Circulating
levels of radioimmunoassayable AVP were significantly lower
in the experimental animals than the AVP concentration in
control animals. The difference in osmotic release of vasopres-
sin was observed despite the fact that the blockers decrease
systemic pressure. Such a decrement in pressure could cause
nonosmolar hormone release and thereby obscure an effect of
the drugs to impair ADH release in response to the hypertonic
solutions. This finding, however, may account for the fact that
the infusion rate of Ca blockers that impaired release in
response to intraperitoneal hyperoncotic dextran was insuffi-
cient to demonstrate abnormal osmotic release (data not
shown). Instead, twice the infusion rate of Ca blockers was
needed to unveil the osmotic effect. This was, in fact, the
maximal dose that permitted the maintenance of a systemic
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Fig. 5. The response of U0,,, to intraperitoneal administration of 6%
den ran. Values given are the mean SEM. The number of observations
is the same as in Figure 4.
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Table 2. Effect of calcium blockers and hyperoncotic dextran on mean arterial pressure, inulin clearance, and plasma osmolality
Yerapamil (N = 14)
Yehick for verapa
(N = 14)
mu
Nifedipine (N = 7)
Yehide for nifedip
(N = 7)
me
Cont Ver Dex Cont Yeh Dex Cont Nif Dex Cont Yeh Dex
MAP, mm Hg
Mean 124.4 l05.7 97.Ib 120.0 119.1 116.0 116.0 106.8 99.4' 115.7 116.1 114.5
2.8 3.3 3.8 2.9 2.6 2.2 3.4 3.9 3.8 4.8 4.7 3.9
P value <0.001 <0.05 NS <0.05 <0.001 <0.01 NS NS
C1, mi/mm
Mean 3.7 3.7 3.6 3.5 3.6 3.2 3.3 3.3 3.0 3.3 3.4 3.4
0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.2 0.1 0.2
P value NS NS NS NS NS NS NS NS
POsm,
mOsm/kg H20
Mean 290.8 291.0 288.1 286.7 290.0 285.7 289.4 290.4 290.2 290.5 290.8 288.9
1.7 2.4 2.4 3.6 2.5 3.2 2.5 2.3 2.4 1.7 1.7 2.4
P value NS NS NS NS NS NS NS NS
Abbreviations: Dex, dextran; see Table 1 for other abbreviations.
P < 0.02 when compared to vehicle treated control in same experimental period.
b p < 0.01 when compared to vehicle treated control in same experimental period.
P < 0.005 when compared to vehicle treated control in same experimental period.
pressure and normal GFR to allow the in vivo studies to be
conducted.
The observation that the administration of the Ca influx
blockers caused a marked decrement in systemic pressure
without significant changes in Uosm suggested a possible im-
pairment in AVP release in response to a hypotensive stimulus.
Thus, further experiments were performed to assess the secre-
tion of AVP in response to a nonosmolar stimulus. The intra-
peritoneal administration of hyperoncotic dextran as described
by Dunn et al [161 and studies from our laboratory [10] provided
a reliable and reproducible hypovolemic (nonosmotic) stimulus.
In these studies, the administration of either of the two blockers
of cellular Ca uptake markedly blunted the increase in Uosm
that accompanied the iritraperitoneal administration of dextran.
This blunted antidiuresis was associated with significantly
lower levels of radioimmunoassayable AVP in animals receiv-
ing the blockers, thus implicating impaired hormone release as
the cause of the lower Uosm. Such a conclusion was supported
by the demonstration that the renal response to exogenous
vasopressin was not altered by either of these cellular Ca
uptake blockers. This failure to observe an end-organ alteration
in vasopressin responsiveness agrees with our results in the
intact dog treated with verapamil, unless inhibitors of prosta-
glandin synthesis are also administered [17]. Verapamil, howev-
er, has been shown to inhibit AVP-mediated osmotic water
movement in the toad bladder in the absence of inhibitors of
prostaglandin synthesis [18].
The observation that blockers of cellular Ca uptake blunt
both osmotic and nonosmotic release allows for some specula-
tion on the possible site at which these agents are acting.
Neurophysiologic studies have suggested strongly that the
osmoreceptor and baroreceptor (nonosmotic) inputs into the
magnocellular neurosecretory neurons in the hypothalamus are
anatomically separate [19]. An action at both of these hypotha-
lamic sites would have to be postulated. Also because Ca
uptake is important not only in hormone but also neurotrans-
mitter release and action [20], it is possible that the blockers of
Ca uptake may have impaired the release of neurotransmitter at
the synapses between osmo- and baroreceptor inputs and the
magnocellular neurosecretory cells. Alternatively, and perhaps
more likely, the effect of the blocker may reside at the posterior
pituitary itself, the final common site of hormone release.
Unfortunately, a differentiation between a hypothalamic or
posterior pituitary site of Ca action has not been provided by in
vitro preparations either. Lastly, because the responses of AVP
release to a nonosmotic stimulus were blunted more easily than
the responses to an osmotic stimulus in the experimental
animals receiving the blockers of cellular Ca uptake, it may be
possible that the input from the baroreceptors themselves to the
afferent parasympathetic pathways that convey the information
to the hypothalamus is blocked by these Ca membrane
blockers. In this regard, it has been noted that baroreceptor
sensitivity can be modified by alteration in the extracellular
I
>
1(
Water Verapamil Verapamil Nifedipine Nifedipine
diuresis vehicle vehicle
Fig. 6. Plasma AVP levels during water diuresis and after the adminis-(ration of hyperoncoilc dextran. Values given are the mean SEM (N =
7).
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concentration of Ca [21]. Further study, however, will be
necessary to assess this last possibility.
Summary. Our experiments reveal that two blockers of
cellular Ca uptake blunted both the osmotic and nonosmotic
release of AVP in the conscious rat. These observations suggest
that blockers of cellular Ca uptake act at the neurohypophysis
itself. However, the possibility that Ca blockers also act at a
site proximal to release AVP from the neurohypophysis such as
the hypothalamus, baroreceptors or osmoreceptors cannot be
ruled out and should be subject of further investigation.
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